All Stories

  1. Identifying predictors of treatment failure with community-acquired pneumonia: an update
  2. Infecciones por el virus respiratorio sincitial en los adultos
  3. Viral community-acquired pneumonia: what’s new since COVID-19 emerged?
  4. Adult vaccinations against respiratory infections
  5. World Pneumonia Day 2024: Fighting Pneumonia and Antimicrobial Resistance
  6. Impact of Empirical Treatment Recommendations From 2017 European Guidelines for Nosocomial Pneumonia
  7. A review of the value of point-of-care testing for community-acquired pneumonia
  8. Diabetes Mellitus and Pneumococcal Pneumonia
  9. Pneumococcal Serotypes Associated with Community-Acquired Pneumonia Hospitalizations in Adults in Spain, 2016–2020: The CAPA Study
  10. World Pneumonia Day 2023: the rising global threat of pneumonia and what we must do about it
  11. Ten Issues for Updating in Community-Acquired Pneumonia: An Expert Review
  12. Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistantStaphylococcus aureuspneumonia
  13. Interventions to improve outcomes in community-acquired pneumonia
  14. The pharmacokinetic evaluation of omadacycline (Oral Only Dosing Regimen) for the treatment of Community-Acquired Bacterial Pneumonia (CABP)
  15. A Novel Approach to Temperature Profiling in Relation to Clinical Outcomes in Oncological Patients with Neutropenia
  16. Características clínicas y epidemiológicas de las muertes por dengue durante un brote en el norte del Perú
  17. Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria: An Official American Thoracic Society Workshop Report
  18. Remdesivir and survival outcomes in critically ill patients with COVID-19: A multicentre observational cohort study
  19. Risk factors associated with mortality among elderly patients with COVID-19: Data from 55 intensive care units in Spain
  20. Advances in molecular diagnostic tests for community-acquired pneumonia
  21. Machine-Learning Model for Mortality Prediction in Patients With Community-Acquired Pneumonia
  22. Estimating the risk of bacteraemia in hospitalised patients with pneumococcal pneumonia
  23. Host-targeted approaches to sepsis due to community-acquired pneumonia
  24. Respiratory viruses: their importance and lessons learned from COVID-19
  25. Early Recognition of Low-Risk SARS-CoV-2 Pneumonia
  26. Aspiration pneumonia
  27. Ceftaroline in severe community-acquired pneumonia
  28. Steroid therapy and antiviral treatment in SARSCoV-2 pneumonia: clinical contexts and indications
  29. Biomarcadores biológicos en las enfermedades respiratorias
  30. [Translated article] Biological Biomarkers in Respiratory Diseases
  31. What's Next in Pneumonia?
  32. Severe Infections Due to Respiratory Viruses
  33. Invasive pulmonary aspergillosis among intubated patients with SARS-CoV-2 or influenza pneumonia: a European multicenter comparative cohort study
  34. Management of pneumonia in critically ill patients
  35. COVID-19 in patients aged 80 years and over during the peaks of the first three pandemic waves at a Spanish tertiary hospital
  36. Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis
  37. Outcomes of Critically ill Very old patients with Acute Respiratory Distress Syndrome and Community-Acquired Pneumonia
  38. Impact on in-hospital mortality of Ceftaroline versus standard of care in Community-Acquired Pneumonia: A Propensity Matched Analysis
  39. The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia
  40. Prediction of ventilator-associated pneumonia outcomes according to the early microbiological response: a retrospective observational study
  41. Pulse oximetry is an essential tool that saves lives: a call for standardisation
  42. Predictive Performance of Risk Factors for Multidrug-Resistant Pathogens in Nosocomial Pneumonia
  43. Pneumonia
  44. Lymphopenia Is Associated With Poor Outcomes of Patients With Community-Acquired Pneumonia and Sepsis
  45. Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia
  46. PES Pathogens in Elderly Patients with Acquired Pneumonia in the Community
  47. Awareness and Pneumonia knowledge: where to start educating?
  48. Methicillin-susceptible Staphylococcus aureus in Community-Acquired Pneumonia: Risk Factors and Outcomes
  49. Systemic Inflammatory Response and Outcomes in Community-Acquired Pneumonia Patients Categorized According to the Smoking Habit or Presence of Chronic Obstructive Pulmonary Disease
  50. SARS-CoV-2–induced Acute Respiratory Distress Syndrome: Pulmonary Mechanics and Gas-Exchange Abnormalities
  51. Promoting the use of social networks in pneumonia
  52. Difficult to treat microorganisms in patients aged over 80 years with community-acquired pneumonia: the prevalence of PES pathogens
  53. Advances in molecular diagnostic tests for pneumonia
  54. Community-acquired pneumonia in critically ill very old patients: a growing problem
  55. Defining Community-Acquired Pneumonia as a Public Health Threat: Arguments in Favor from Spanish Investigators
  56. Can Artificial Intelligence Improve the Management of Pneumonia
  57. Reply to Musher
  58. Macrolide combination therapy for hospitalised CAP patients? An individualised approach supported by machine learning
  59. Pneumocystis pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients
  60. Prevalence and risk factors of sepsis in very old patients with CAP
  61. Ventilator-Associated Pneumonia and PaO2/FIO2 Diagnostic Accuracy: Changing the Paradigm?
  62. Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired Pneumonia
  63. non invasive diagnosis of nosocomial pneumonia
  64. Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia
  65. Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired pneumonia
  66. lymphopenia predicts mortality in patients with ICU pneumonia
  67. Addendum: Cillóniz, C.; Dominedò, C.; Nicolini, A.; Torres, A. PES Pathogens in Severe Community-Acquired Pneumonia. Microorganisms 2019, 7, 49
  68. Evaluation of the Magicplex™ Sepsis Real-Time Test for the Rapid Diagnosis of Bloodstream Infections in Adults
  69. Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia
  70. PES Pathogens in Severe Community-Acquired Pneumonia
  71. An international perspective on hospitalized patients with viral community-acquired pneumonia
  72. Early noninvasive ventilation treatment for respiratory failure due to severe community-acquired pneumonia
  73. Community-acquired pneumonia as an emergency condition
  74. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients with Community-Acquired Pneumonia
  75. Reply to Head and Keynan
  76. Drugs that increase the risk of community-acquired pneumonia: a narrative review
  77. Treating HIV-Positive/Non-AIDS Patients for Community-Acquired Pneumonia with ART
  78. Clinical Approach to Community-acquired Pneumonia
  79. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study
  80. Inflammatory response depends on time since onset of symptoms in pneumonia
  81. MagicplexTM Sepsis real-time test for the rapid diagnosis of bloodstream infections in adults
  82. Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia
  83. Burden and risk factors forPseudomonas aeruginosacommunity-acquired pneumonia: a multinational point prevalence study of hospitalised patients
  84. Community-acquired bacterial pneumonia in adult HIV-infected patients
  85. Microorganisms resistant to conventional antimicrobials in acute exacerbations of chronic obstructive pulmonary disease
  86. Community-acquired Pneumonia and Acute Respiratory Distress Syndrome
  87. Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging
  88. Community-Acquired Legionella Pneumonia in Human Immunodeficiency Virus–Infected Adult Patients: A Matched Case-Control Study
  89. Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review
  90. Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysis
  91. Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia
  92. Detection of human cytomegalovirus in bronchoalveolar lavage of intensive care unit patients
  93. Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients
  94. New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality. A Validation and Clinical Decision-Making Study
  95. Respiratory infection: insights from Assembly 10 of the European Respiratory Society 2017 Annual Congress
  96. Has Mortality of Community-Acquired Pneumonia Really Reduced?
  97. Predictors of treatment failure and clinical stability in patients with community acquired pneumonia
  98. Adjuvant therapies in critical care: steroids in community-acquired pneumonia
  99. Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia
  100. Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality
  101. Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia
  102. The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study
  103. Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia
  104. Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients
  105. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial
  106. Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia
  107. Risk factors for community-acquired pneumonia in adults
  108. Antibiotic therapy prior to hospital admission is associated with reduced septic shock and need for mechanical ventilation in patients with community-acquired pneumonia
  109. Typical Presentation of Legionella pneumophila Community-Acquired Pneumonia
  110. Research in community-acquired pneumonia: the next steps
  111. Seasonality of pathogens causing community-acquired pneumonia
  112. Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns
  113. Laboratory diagnosis of pneumonia in the molecular age
  114. Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome
  115. Clinical management of community acquired pneumonia in the elderly patient
  116. Community-Acquired Pneumonia 2000-2015: What is New?
  117. Response
  118. Community-Acquired Pneumonia Due to Multidrug- and Non–Multidrug-Resistant Pseudomonas aeruginosa
  119. Community-acquired pneumonia related to intracellular pathogens
  120. Predictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumonia
  121. What is the clinical relevance of drug-resistant pneumococcus?
  122. Multilobar bilateral and unilateral chest radiograph involvement: implications for prognosis in hospitalised community-acquired pneumonia
  123. Pneumococcal vaccination
  124. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis
  125. Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis
  126. Severe community-acquired pneumonia: Corticosteroids as adjunctive treatment to antibiotics
  127. Bronchiectasis in rare pulmonary diseases: A case series
  128. Bacteraemia in outpatients with community-acquired pneumonia
  129. Polymicrobial community-acquired pneumonia: An emerging entity
  130. Sensitivity, Specificity, and Positivity Predictors of the Pneumococcal Urinary Antigen Test in Community-Acquired Pneumonia
  131. Bacteraemia in outpatient with community-acquired pneumonia
  132. Ceftobiprole for the treatment of pneumonia: a European perspective
  133. Streptococcus pneumoniae-associated pneumonia complicated by purulent pericarditis: case series
  134. Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients
  135. New antimicrobial approaches to gram positive respiratory infections
  136. Macrolide resistance and outcomes of patients with Streptococcus pneumoniae pneumonia.
  137. Risk Factors Associated with Potentially Antibiotic-Resistant Pathogens in Community-Acquired Pneumonia
  138. Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis
  139. Severe community-acquired pneumonia: Severity and management
  140. Noninvasive ventilation for acute respiratory failure due to community-acquired pneumonia: A concise review and update
  141. Clinical Management of Bacterial Pneumonia
  142. Viral infections
  143. Detection of Pneumonia Associated Pathogens Using a Prototype Multiplexed Pneumonia Test in Hospitalized Patients with Severe Pneumonia
  144. Severity and outcomes of community acquired pneumonia in asthmatic patients
  145. Predicting treatment failure in patients with community acquired pneumonia: a case-control study
  146. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
  147. Lung abscess due to Streptococcus pneumoniae: a case series and brief review of the literature
  148. Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study
  149. Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome
  150. IgA level in plasma as a differential factor for influenza infection in severe viral pneumonia
  151. Pneumococcal disease: Epidemiology and new vaccines
  152. Community-acquired viral pneumonia in human immunodeficiency virus infected patients
  153. Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis
  154. Predicting Community-Acquired Pneumonia Etiology: Response
  155. A Worldwide Perspective of Nursing Home-Acquired Pneumonia Compared With Community-Acquired Pneumonia
  156. IgM levels in plasma predict outcome in severe pandemic influenza
  157. Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case–control study
  158. Impact of Age and Comorbidity on Cause and Outcome in Community-Acquired Pneumonia
  159. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective: Table 1
  160. Influence of Previous Use of Inhaled Corticoids on the Development of Pleural Effusion in Community-acquired Pneumonia
  161. Thrombocytosis Is a Marker of Poor Outcome in Community-Acquired Pneumonia
  162. Epidemiology, Clinical Features, and Prognosis of Elderly Adults with Severe Forms of Influenza A (H1N1)
  163. Systemic corticosteroids for community-acquired pneumonia: Reasons for use and lack of benefit on outcome
  164. Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia
  165. Influenza A (H1N1) Pneumonia
  166. Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes
  167. Invasive Pneumococcal Disease Today
  168. Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia
  169. Entendimento da mortalidade em pneumonia pneumocócica bacterêmica
  170. Cytokine Activation Patterns and Biomarkers Are Influenced by Microorganisms in Community-Acquired Pneumonia
  171. Pulmonary Complications Of Pneumococcal CAP: Incidence, Predictors, And Outcomes
  172. Corticosteroids In Community-Acquired Pneumonia: Therapeutic Reasons And Outcomes
  173. Influence Of Long-Term Use Of Inhaled Corticoids On The Development Of Pleural Effusion In Community Acquired Pneumonia
  174. Thrombocytosis Is A Diagnostic And Prognostic Marker In Community-Acquired Pneumonia
  175. Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza
  176. Community-acquired pneumonia in outpatients: aetiology and outcomes
  177. CD4+ cell counts and HIV-RNA levels do not predict outcomes of community-acquired pneumonia in hospitalized HIV-infected patients
  178. CAP IN COPD PATIENTS
  179. Clinical relevance of mixed respiratory viral infections in adults with influenza A H1N1
  180. First influenza season after the 2009 pandemic influenza: report of the first 300 ICU admissions in Spain
  181. Microbial aetiology of community-acquired pneumonia and its relation to severity
  182. Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis
  183. Pandemic and post-pandemic Influenza A (H1N1) infection in critically ill patients
  184. Influenza pneumonia: a comparison between seasonal influenza virus and the H1N1 pandemic
  185. Correction
  186. Factors associated with inflammatory cytokine patterns in community-acquired pneumonia
  187. Severe Mixed Community Acquired Pneumoniae
  188. Community-acquired Pneumonia In Outpatients: Microbial Etiology
  189. INDICATION OF PLEURAL DRAINAGE IN PARAPNEUMONIC EFFUSION: ADHERENCE TO THE AMERICAN COLLEGE OF CHEST PHYSICIANS’ GUIDELINES
  190. PARAPNEUMONIC EFFUSIONS ACCORDING TO THE CLASSIFICATION OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS: CLINICAL CHARACTERISTICS
  191. Healthcare-associated Pneumonia (HCAP): Clinical Features And Biomarkers
  192. Nursing home-acquired pneumonia: a 10 year single-centre experience
  193. Impact of Smoking Habit on the Etiology of Community-Acquired Pneumonia (CAP).
  194. Community-Acquired Pneumonia: Etiology and Severity Scores.
  195. Complicated Pneumococcal Pneumonia in Adults.
  196. Severe community-acquired pneumonia